Summary of Price Reductions for Drugs Subject to Price Disclosure pre-1 December 2010

First Round of PBS Price Disclosure – 1 December 2009

Drug	MOA	Weight average percentage reduction
Doxorubicin	Injection / intravesical	63.54%
Mitozantrone	Injection	34.42%
Ondansetron	Injection	15.37%

 

Second Round of PBS Price Disclosure – 1 April 2010

Drug	MOA	Weight average percentage reduction
Fluconazole	Oral	55.26%
Vancomycin	Injection	71.80%

 

Third Round of PBS Price Disclosure – 1 April 2010

Drug	MOA	Weight average percentage reduction
Carvedilol	Oral	27.29%

 

Fourth Round of PBS Price Disclosure – 1 August 2010

Drug	MOA	Weight average percentage reduction
Cefalotin	Injection	41.13%
Doxorubicin	Injection / intravesical	34.62%
Meloxicam	Oral	17.99%
Mitozantrone	Injection	13.33%
Ondansetron	Injection	17.61%

 

Fifth Round of PBS Price Disclosure – 1 April 2011

Drug	MOA	Weight average percentage reduction
Alendronic Acid	Oral	22.96%
Cisplatin	Injection	39.02%
Fluconazole	Injection	27.52%
Fluconazole	Oral	38.48%
Risperidone	Oral	17.37%
Vancomycin	Injection	12.48%

 

Sixth Round of PBS Price Disclosure – 1 April 2011

Drug	MOA	Weight average percentage reduction
Carvedilol	Oral	11.90%
Gemcitabine	Injection	37.00%
Irinotecan	Injection	61.40%
Paclitaxel	Injection	52.58%

 

Seventh Round of PBS Price Disclosure – 1 August 2011

Drug	MOA	Weight average percentage reduction
Bicalutamide	Oral	10.31%
Escitalopram	Oral	33.80%
Meloxicam	Oral	12.40%
Mitozantrone	Injection	10.61%
Ondansetron	Oral	39.44%
Ondansetron	Injection	22.51%
Oxaliplatin	Injection	72.54%
Sodium Chloride	Injection	43.54%
Sodium Lactate Compound	Injection	45.61%
Valproic Acid	Oral	10.83%